Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01988896
Title A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

melanoma

lung non-small cell carcinoma

colorectal cancer

Advanced Solid Tumor

Therapies

Atezolizumab + Cobimetinib

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.